Mazahreh R, Mason ML, Gosink JJ, Olson DJ, et al. SGN-CD228A Is an Investigational CD228-Directed Antibody-Drug Conjugate with Potent Antitumor Activity across a Wide Spectrum of Preclinical Solid Tumor Models. Mol Cancer Ther 2023;22:421-434.
PMID: 36800443